Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TIMOTHY J PANELLA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1801908223
CMS profile
172406
Location
KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$2,726.53

138 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,526.59 136
Education $199.94 2

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TIMOTHY J PANELLA

NPI 1801908223 · CMS profile ID 172406

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801908223?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TIMOTHY J PANELLA, NPI 1801908223, CMS profile ID 172406. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801908223?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). TIMOTHY J PANELLA, NPI 1801908223, CMS profile ID 172406. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801908223?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
TIMOTHY J PANELLA, NPI 1801908223, CMS profile ID 172406, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 138 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1801908223?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

138 matching records · $2,726.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 138 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 138.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $20.3808/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223860622 CMS
Merck Sharp & Dohme LLC $15.5308/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238301665 CMS
Merck Sharp & Dohme LLC $24.4208/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238109040 CMS
Regeneron Healthcare Solutions, Inc. $23.3808/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213006268 CMS
ABBVIE INC. $24.1808/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203449405 CMS
Regeneron Pharmaceuticals, Inc. $38.1308/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213241759 CMS
Genentech USA, Inc. $17.2707/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211601448 CMS
Immunocore Limited $26.7307/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235825494 CMS
Merck Sharp & Dohme LLC $14.9307/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238072272 CMS
Merck Sharp & Dohme LLC $23.7507/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238169094 CMS
Novartis Pharmaceuticals Corporation $23.3907/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200690702 CMS
Gilead Sciences, Inc. $16.3707/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234562899 CMS
Syndax Pharmaceuticals, Inc. $16.3607/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238994018 CMS
AstraZeneca Pharmaceuticals LP $32.4307/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207250538 CMS
E.R. Squibb & Sons, L.L.C. $5.2407/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184892638 CMS
ABBVIE INC. $19.9607/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203449401 CMS
E.R. Squibb & Sons, L.L.C. $11.3907/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184892640 CMS
Regeneron Healthcare Solutions, Inc. $16.1407/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213006266 CMS
E.R. Squibb & Sons, L.L.C. $21.4706/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184892630 CMS
Novartis Pharmaceuticals Corporation $19.6606/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200690694 CMS
E.R. Squibb & Sons, L.L.C. $10.1106/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184892642 CMS
E.R. Squibb & Sons, L.L.C. $8.5806/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184892628 CMS
Genentech USA, Inc. $20.8206/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211601452 CMS
Deciphera Pharmaceuticals Inc. $17.8906/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235960663 CMS
Merck Sharp & Dohme LLC $25.3006/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238177929 CMS
Regeneron Healthcare Solutions, Inc. $21.8706/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213006264 CMS
Blueprint Medicines Corporation $23.4206/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235813849 CMS
Merck Sharp & Dohme LLC $16.5606/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238022182 CMS
Novartis Pharmaceuticals Corporation $16.1606/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200690688 CMS
E.R. Squibb & Sons, L.L.C. $7.2206/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184892644 CMS
Regeneron Healthcare Solutions, Inc. $33.6406/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213006262 CMS
Incyte Corporation $19.8606/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226123075 CMS
ADC THERAPEUTICS AMERICA, INC. $17.5405/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246127341 CMS
Merck Sharp & Dohme LLC $17.2705/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238264996 CMS
Gilead Sciences, Inc. $6.6205/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234596501 CMS
PFIZER INC. $15.8905/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231327819 CMS
Exelixis Inc. $24.4605/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218806659 CMS
Gilead Sciences, Inc. $18.6605/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234542663 CMS
E.R. Squibb & Sons, L.L.C. $9.8405/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184892604 CMS
Regeneron Pharmaceuticals, Inc. $32.4705/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213241757 CMS
PUMA BIOTECHNOLOGY, INC. $14.0105/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251745426 CMS
Janssen Biotech, Inc. $17.6604/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174865070 CMS
Agios Pharmaceuticals, Inc. $19.5304/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253246128 CMS
Gilead Sciences, Inc. $25.2904/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234471912 CMS
Novartis Pharmaceuticals Corporation $11.5304/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200690682 CMS
E.R. Squibb & Sons, L.L.C. $18.5104/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184892612 CMS
Merck Sharp & Dohme LLC $14.1004/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238259229 CMS
Celgene Corporation $20.2504/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184892594 CMS
Daiichi Sankyo Inc. $19.3304/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197060207 CMS
E.R. Squibb & Sons, L.L.C. $10.8504/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184892590 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,320.36 169
PY2020 $554.52 38
PY2021 $781.56 50
PY2022 $1,431.85 83
PY2023 $2,470.40 138
PY2024 $2,928.13 145
PY2025 $2,726.53 138

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $693.33 2
PY2025 Principal investigator $845,696.75 344
PY2024 Recipient $5,166.06 2
PY2024 Principal investigator $441,512.56 140
PY2023 Recipient $9,588.72 30
PY2023 Principal investigator $274,060.55 82
PY2022 Recipient $6,062.10 15
PY2022 Principal investigator $203,797.88 43
PY2021 Recipient $4,470.00 3
PY2021 Principal investigator $689,400.90 45
PY2020 Principal investigator $445,623.55 29
PY2019 Principal investigator $587,903.01 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

346 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $291.82 12/31/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - KEYNOTE-355 No dispute reported 06/30/2026 1232926323
Principal investigator 1 Merck Sharp & Dohme LLC $11,443.75 12/31/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 1232926413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,855.20 12/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184140347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,573.78 12/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,964.20 12/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $437.43 12/04/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,151.67 12/04/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 11/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $550.00 11/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 11/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,781.63 11/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 11/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 11/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 11/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 11/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $331.66 11/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,325.14 11/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 11/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 11/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 11/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 11/19/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,678.56 11/14/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 11/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 11/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 11/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 11/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 11/05/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 11/05/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 11/05/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 11/05/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,776.34 11/05/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.13 11/05/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 10/30/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 10/30/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,781.63 10/30/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 10/30/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 10/30/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $550.00 10/30/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 10/30/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,530.00 10/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.63 10/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 10/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 10/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 10/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 10/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $605.00 10/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 10/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,621.38 10/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $219.93 10/23/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,150.21 10/23/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140231
Principal investigator 1 Immunocore Limited $1,282.88 10/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 10/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,781.63 10/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 10/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $550.00 10/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 10/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 10/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 10/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,573.78 10/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,964.20 10/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $107.82 10/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,001.46 10/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,946.95 09/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $625.60 09/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140152
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $625.60 09/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140156
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,470.50 09/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,470.50 09/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,470.50 09/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 09/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,708.10 09/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,714.05 09/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,777.80 09/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,946.95 09/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 09/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,301.35 09/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 09/29/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 09/25/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140122
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.63 09/25/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140126
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 09/25/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140130
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 09/25/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,530.00 09/25/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 09/25/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140144
Principal investigator 1 Immunocore Limited $1,271.88 09/24/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 09/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 09/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 09/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,530.00 09/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140110
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 09/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.63 09/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,097.17 09/18/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 09/17/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140076
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.04 09/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $312.00 09/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,150.21 09/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184140072
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 09/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140038
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 09/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.63 09/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,530.00 09/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 09/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 09/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.63 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139996
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,530.00 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140006
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140010
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 09/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184140014
Principal investigator 1 Ascendis Pharma Endocrinology Inc $1,200.00 08/26/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BelieveIT-201 No dispute reported 06/30/2026 1233996715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,001.46 08/26/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139986
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $208.00 08/21/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11.93 08/21/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,001.46 08/21/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139967
Principal investigator 1 AstraZeneca UK Limited $14,111.90 08/15/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease No dispute reported 06/30/2026 1185552735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 08/14/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139948
Principal investigator 1 Immunocore Limited $605.00 08/13/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146317
Principal investigator 1 Immunocore Limited $1,175.63 08/13/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146319
Principal investigator 1 Immunocore Limited $673.75 08/13/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 08/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139888
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 08/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,115.25 08/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,609.90 08/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139900
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,946.95 08/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139904
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,777.80 08/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $625.60 08/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 08/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139916
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,714.05 08/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139920
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,714.05 08/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,946.95 08/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,714.05 08/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,470.50 08/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,946.95 08/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 08/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139944
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,150.21 08/07/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139884
Principal investigator 1 Ascendis Pharma Endocrinology Inc $239.26 08/04/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BelieveIT-201 No dispute reported 06/30/2026 1233996633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,150.21 07/31/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.64 07/22/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $208.00 07/22/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139859
Principal investigator 1 Immunocore Limited $673.75 07/18/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146323
Principal investigator 1 Immunocore Limited $605.00 07/18/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146325
Principal investigator 1 Immunocore Limited $1,271.88 07/18/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146327
Principal investigator 1 Immunocore Limited $605.00 07/18/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,001.46 07/17/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139832
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 07/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 07/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $416.00 07/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.44 07/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,001.46 07/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,710.40 07/10/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184139819
Principal investigator 1 Immunocore Limited $1,100.00 07/02/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146307
Principal investigator 1 Immunocore Limited $3,616.25 07/02/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146309
Principal investigator 1 Immunocore Limited $605.00 07/02/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146311
Principal investigator 1 Immunocore Limited $605.00 07/02/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146313
Principal investigator 1 Immunocore Limited $1,443.75 07/02/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 06/30/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139772
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.13 06/30/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 06/30/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,776.13 06/30/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139782
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 06/30/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 06/30/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139790
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.63 06/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 06/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139734
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 06/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $605.00 06/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $605.00 06/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,530.00 06/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139752
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 06/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139756
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 06/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,621.38 06/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,621.38 06/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,257.42 06/24/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139728
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 06/23/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139720
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $512.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $512.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $512.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $625.60 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $625.60 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $787.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,022.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,022.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,056.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,097.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,107.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,107.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,173.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,191.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,230.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,297.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,297.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,331.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,382.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,382.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,538.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,578.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,877.25 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,877.25 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,946.95 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,946.95 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,946.95 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,115.25 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139694
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,255.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,220.00 06/16/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,150.21 06/12/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,279.40 06/05/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,378.00 06/05/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,573.78 06/05/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139615
Recipient Regeneron Pharmaceuticals, Inc. $539.20 06/01/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184121157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $625.60 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,946.95 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,946.95 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,959.30 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,968.20 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,852.20 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,115.25 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $625.60 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,959.30 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,852.20 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,115.25 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,946.95 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,877.25 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,777.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,959.30 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,777.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,777.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,708.10 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,115.25 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,115.25 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,714.05 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,852.20 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,946.95 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,968.20 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,777.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,946.95 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,777.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,777.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,968.20 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,301.35 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,539.80 05/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,001.46 05/27/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,781.63 05/23/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 05/23/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $550.00 05/23/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 05/23/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 05/23/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 05/23/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,621.38 05/23/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $605.00 05/23/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 05/22/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184139487
Principal investigator 1 Ascendis Pharma Endocrinology Inc $250.00 05/21/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
TranscendIT-101 No dispute reported 06/30/2026 1233995657
Principal investigator 1 Immunocore Limited $189.00 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146275
Principal investigator 1 Immunocore Limited $189.00 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146277
Principal investigator 1 Immunocore Limited $9,704.75 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146279
Principal investigator 1 Immunocore Limited $199.38 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146281
Principal investigator 1 Immunocore Limited $9,704.75 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146283
Principal investigator 1 Immunocore Limited $4,452.25 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146285
Principal investigator 1 Immunocore Limited $2,145.00 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146287
Principal investigator 1 Immunocore Limited $2,557.50 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146289
Principal investigator 1 Immunocore Limited $4,083.75 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146291
Principal investigator 1 Immunocore Limited $1,072.50 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146293
Principal investigator 1 Immunocore Limited $605.00 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146295
Principal investigator 1 Immunocore Limited $3,984.75 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146297
Principal investigator 1 Immunocore Limited $1,677.50 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146299
Principal investigator 1 Immunocore Limited $1,475.38 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146301
Principal investigator 1 Immunocore Limited $1,100.00 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146303
Principal investigator 1 Immunocore Limited $1,168.75 05/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146305
Principal investigator 1 Ascendis Pharma Endocrinology Inc $23,674.76 05/15/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BelieveIT-201 No dispute reported 06/30/2026 1233995605
Principal investigator 1 Ascendis Pharma Endocrinology Inc $500.00 05/15/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BelieveIT-201 No dispute reported 06/30/2026 1233995619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 05/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 05/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 05/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 05/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,257.42 05/08/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,825.00 05/02/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184139469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,552.00 05/02/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184139471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 05/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.63 05/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 05/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 05/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 05/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,530.00 05/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139467
Principal investigator 1 Ascendis Pharma Endocrinology Inc $2,406.25 04/17/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
TranscendIT-101 No dispute reported 06/30/2026 1233995525
Principal investigator 1 Immunocore Limited $189.00 04/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146259
Principal investigator 1 Immunocore Limited $189.00 04/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146261
Principal investigator 1 Immunocore Limited $1,942.88 04/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146263
Principal investigator 1 Immunocore Limited $1,567.50 04/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146265
Principal investigator 1 Immunocore Limited $1,636.25 04/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146267
Principal investigator 1 Immunocore Limited $1,911.25 04/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146269
Principal investigator 1 Immunocore Limited $1,567.50 04/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146271
Principal investigator 1 Immunocore Limited $2,090.00 04/16/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $589.88 04/14/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,814.63 04/14/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,746.88 04/14/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 04/14/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139435
Principal investigator 1 Ascendis Pharma Endocrinology Inc $2,252.24 04/11/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
TranscendIT-101 No dispute reported 06/30/2026 1233995323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139427
Principal investigator 1 Eli Lilly and Company $4,035.00 04/08/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187875469
Recipient Regeneron Pharmaceuticals, Inc. $154.13 03/25/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184121155
Principal investigator 1 Ascendis Pharma Endocrinology Inc $250.00 03/19/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
TranscendIT-101 No dispute reported 06/30/2026 1233995221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 03/17/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139417
Principal investigator 1 Eli Lilly and Company $2,000.20 03/10/2025 Non-covered Recipient Entity
UNIVERSITY OF TENNESSEE
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187893392
Principal investigator 1 Ascendis Pharma Endocrinology Inc $6,943.50 03/06/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
TranscendIT-101 No dispute reported 06/30/2026 1233995155
Principal investigator 1 Ascendis Pharma Endocrinology Inc $300.00 02/20/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BelieveIT-201 No dispute reported 06/30/2026 1233994847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $605.00 02/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,621.38 02/20/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139409
Principal investigator 1 Immunocore Limited $250.00 02/03/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,592.50 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,224.45 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,394.45 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,199.35 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,421.65 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,983.05 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,153.90 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,421.65 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,153.90 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,421.65 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,224.45 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,983.05 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,592.50 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,153.90 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,224.45 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,983.05 02/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184139403
Principal investigator 1 BioNTech SE $5,000.00 01/29/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-02 No dispute reported 06/30/2026 1249014347
Principal investigator 1 BioNTech SE $2,900.00 01/29/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-02 No dispute reported 06/30/2026 1249014349
Principal investigator 1 BioNTech SE $12,000.00 01/29/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
BNT327-02 No dispute reported 06/30/2026 1249014351
Principal investigator 1 Immunocore Limited $9,705.00 01/24/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146247
Principal investigator 1 Immunocore Limited $189.00 01/24/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146249
Principal investigator 1 Immunocore Limited $189.00 01/24/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146251
Principal investigator 1 Immunocore Limited $189.00 01/24/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146253
Principal investigator 1 Immunocore Limited $189.00 01/24/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146255
Principal investigator 1 Immunocore Limited $189.00 01/24/2025 Non-covered Recipient Entity
University Health System, Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146257
Principal investigator 1 AstraZeneca UK Limited $19,469.85 01/22/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185552733
Principal investigator 1 Ascendis Pharma Endocrinology Inc $25,095.25 01/14/2025 Covered Recipient Teaching Hospital
University Of Tennessee Medical Cent
TranscendIT-101 No dispute reported 06/30/2026 1233993932
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,885.00 01/13/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 01/13/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139363
Principal investigator 1 Eli Lilly and Company $36,473.00 01/06/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF TENNESSEE MEDICAL CENT
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187875467